Aegirbio - iSTOC collaboration 2022

Aegirbio and iSTOC to cooperate with a data management platform

Categories: Partnerships | Covid19 | News

We are pleased to announce the initiation of a development and licensing agreement with Aegirbio. The agreement covers the development of a data management platform for the Aegirbio’s recently CE marked Magnia Reader based natalizumab antibody point of care TDM test.

The deliverables will include a web-based information dashboard and a mobile app to sync data readouts from the Magnia Reader both wirelessly and seamlessly. This platform will provide an interface between electronic medical records and will form a foundation for easy integration of Aegirbio’s assays into clinical, POC, and at home work-flows, both for up-coming trials and everyday patient care.

“In modern point of care and point of need testing, data handling and presentation is as important as the accuracy of the test. We reviewed many potential solutions and ultimately chose the iSTOC platform because of its flexibility, data security, and established regulatory acceptance. With real world clinical studies about to begin, we identified that it was critical to get this component of our total solution in development. A successful project with this product will open the door for future collaborations with our growing portfolio of assays and we look forward to a fruitful partnership with the iSTOC team”, states Bradley Messmer, the CEO of Aegirbio.

Jarmo Järvenpää, the CEO of iSTOC is looking forward to developing the platform with Aigerbio; “We are excited to start collaborating with Aegirbio and combining our strengths in this platform project as well as in future ventures.”

Aegirbio is a joint venture combining core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Lund, Sweden, and owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a San Diego, California, based biotech and has developed the Veritope chemistry platform for detecting levels of biologic drugs in patient samples. Following several years of successful collaboration, Lifeassays and Abreos Biosciences will combine their highly complementary technologies in Aegirbio to create a leader in therapeutic drug monitoring of biologic drugs.

iSTOC, together with partners around the globe, focus on diagnostic technologies and epidemic surveillance forming Point-of-Care chains from remote testing to diagnosis and treatment, including data management, measuring and monitoring. iSTOC has developed a disruptive, end-to-end IDA (immediate diagnostics and analytics) mobile solution, a powerful product and service that integrates Point of Care diagnostics, machine vision, AI, mobile technology and cloud computing. iSTOC IDA Platform digitalizes and analyses Rapid Diagnostic Tests (RDT), including all major infectious diseases as well as blood typing, female and reproductive health and drugs of abuse.